|Bid||1,425.00 x 0|
|Ask||1,426.00 x 0|
|Day's Range||1,422.00 - 1,448.00|
|52 Week Range||1,041.00 - 1,489.00|
|PE Ratio (TTM)||65.30|
|Earnings Date||Nov 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||1,515.31|
Genmab A/S and Seattle Genetics, Inc. announced today that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development.
Gains by cyclical sectors helped push European stocks higher on Thursday while heavy losses in Dixons Carphone after a profit warning dominated trading. Dixons Carphone shares plummeted as much as 29 percent after the mobile phone retailer downgraded expectations for full-year profit, reflecting tougher conditions in the mobile market as customers hold on to handsets for longer. "With the December results some way off and Black Friday week (of retail discounts) looming, Dixons will be under pressure to provide additional detail on today's complex variables in coming weeks," said Stifel analysts.
Q2 2017 Genmab A/S Earnings Call